中 EN

投资者关系 > 详情

Anti-Heart Failure Drug -- rhNRG-1 has Complete Chinese Phase II Clinical Trials

2011-01-11

Zensun has competed Chinese Phase II Clinical Trials of its innovative anti-heart failure drug — rhNRG-1. Part of results were published in JACC. Our outcomes have been specially reported by Reuters' the Doctor Channel. http://www.thedoctorschannel.com/video/3204.html

更多动态

Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
ISS&ISE Reports Have Been Submitted to the FDA
Zensun Successfully Raised Approximately ¥504 million (US$76 million)
Zensun’s Listing Ceremony Held In Beijing For The Initial Listing Of Shares
ZS-07 shows positive results in an animal model of Alzheimer’s disease
Neucardin™ Phase III clinical trial (ZS-01-305) is now unblinding and analyzing data
Exciting results from the Neucardin™ Phase III clinical trial (Interim Analysis)
Zensun was presented “Frost & Sullivan´s 2016 Growth, Innovation and Leadership Awards”
Promising progress on a breakthrough therapy for severe heart failure
Mini-sonic and Portable Cardiogram Monitor by Zensun Will Be Commercialized in 2016
An International Multi-center Phase III Clinical Trial of Recombinant Human Neuregulin-1 is going to
Zensun Announces Successful End of Phase 2 Meeting for Neucardin™
Zensun Announces Positive Results for Neucardin™ to Improve Heart Function and Reduce Mortality
Zensun Obtained the Exciting Results of US Phase II Clinical Trial
Phase II Clinical Trial of rhNRG-1 is Near Completion
Zensun has Submitted NDA of rhNRG-1 to SFDA
Chinese Phase III Clinical Trials of rhNRG-1 are Recruiting Patients
Zensun Sucessfully Finished New Round of Financing
Anti-Heart Failure Drug -- rhNRG-1 has Complete Chinese Phase II Clinical Trials
The Survival Study of rhNRG-1 Obtained Satisfying Result
rhNRG-1 Obtained SFDA Approval for Phase III Clinical Trial
Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1
Phase II Clinical Trials Results of rhNRG-1 have been Published in JACC
Zensun Got New Investment to Accelerate Phase III Clinical Trial of rhNRG-1
rhNRG-1 Phase II Clinical study Showed a Significant Decrease of Rehospitalization
An Article Published in Cell Demonstrated the Similar Mechanism as Zensun Discovered In July 24th
rhNRG-1 was Approved to Take Phase II Clinical Trial in US
Zensun Obtained Breakthrough Results in the Treatment of Heart Failure
Zensun was Reported by Media Worldwide
Zensun Completed Chinese Phase II Clinical Study of rhNRG-1
Zensun Finished Patients Recruitment of rhNRG-1’s Phase II b Clinical Trial in China
Zensun Achieved Important Progress in Australian Phase II clinical Trial
Effects of rhNRG-1 on Cardiac Function Improvements was Verified by the Recent Scientific Experiment
Zensun Obtained Initial Results of Australian Clinical Study
Minister of Science and Technology Visited Zensun
Zensun Successfully Passed the Mid-Term Evaluation of Science Prosperity Program
Article’s about rhNRG-1’s Animal Model Study was Commented by JACC Editors
Zensun Had a Meeting With the Expert Panel of FDA
Shanghai Sci & Tech Committee and Shanghai Venture Capital Visited Zensun
Zensun´s rhNRG-1 Project has passed the Preliminary Evaluation by Boehringer-Ingelheim
rhNRG-1 and rhErbB3-f were recognized as "Shanghai high-tech achievement transformation projects"
rhNRG-1 and rhErbB3-f were Selected to “Shanghai Sci & Tech Prosperity Program” and “Huiyan Program”

ABOUT ZENSUN

SCIENCE

Pipeline

INVESTOR RELATIONS

CAREERS

CONTACT US

  • Zensun
  • Address：68JuLiRoad,ZhangjiangHi-TechParkShanghai,P.R.China
  • Tel:86-021-50802627
  • ZensunUSA
  • Address：12636HighBluffDr,Suite130,SanDiego,CA92130
  • Tel：858-450-9835

地址：上海市浦东张江高科技园区居里路68号沪ICP备06030993号-2